Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Other Operating Expenses (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Other Operating Expenses for 14 consecutive years, with -$420.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses fell 3517.89% year-over-year to -$420.4 million, compared with a TTM value of $69.5 million through Dec 2025, down 81.92%, and an annual FY2025 reading of $69.5 million, up 49.46% over the prior year.
  • Other Operating Expenses was -$420.4 million for Q4 2025 at Neurocrine Biosciences, down from $14.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $357.6 million in Q3 2023 and bottomed at -$420.4 million in Q4 2025.
  • Average Other Operating Expenses over 4 years is $86.9 million, with a median of $83.4 million recorded in 2023.
  • Peak annual rise in Other Operating Expenses hit 58.89% in 2025, while the deepest fall reached 3517.89% in 2025.
  • Year by year, Other Operating Expenses stood at $8.1 million in 2021, then rose by 4.94% to $8.5 million in 2023, then surged by 44.71% to $12.3 million in 2024, then tumbled by 3517.89% to -$420.4 million in 2025.
  • Business Quant data shows Other Operating Expenses for NBIX at -$420.4 million in Q4 2025, $14.3 million in Q3 2025, and $240.6 million in Q2 2025.